Lilly Asia Ventures Receives $40M Commitment From US Pension Fund SFERS

Login to View

Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has received a commitment of US$40 million for its fifth biosciences fund, LAV Biosciences Fund V, from U.S. public pension San Francisco City & County Employees’ Retirement System (SFERS).

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info


Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in


RELATED NEWS